Clinical trial
Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With…
NCT00469859 · Children's Oncology Group, Other · Completed
Key facts
| NCT number | NCT00469859 |
|---|---|
| Title | Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia |
| Official title | A Pilot Study of Lestaurtinib (CEP-701) in Combination With Chemotherapy in Young Patients With Relapsed or Refractory FLT3-mutant Acute Myeloid Leukemia |
| Lead sponsor | Children's Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | cytarabine, idarubicin, lestaurtinib |
| Enrollment | 14 |
| Start date | Jun 1, 2007 |
| Primary completion | Mar 1, 2010 |
| Completion | Mar 1, 2010 |
| First posted | May 7, 2007 |
| Last update posted | Mar 15, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: